Clinical trials: Polycystic Kidney Diseases
Autosomal Dominant Polycystic Kidney Disease
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function…
- Trial name
- NCT04939935
- Testing
- Metformin XR, Control
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 1,174 people
- Sponsor
- The University of Queensland
Kidney, Polycystic, Autosomal Dominant
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT00890279
- Testing
- Cilnidipine, Imidapril
- Where
- 9 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Autosomal Dominant Polycystic Kidney Disease
Managing Depressive Symptoms in ADPKD
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic…
- Trial name
- NCT07745920
- Testing
- Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Bempedoic Acid Therapy for Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD), the most commonly inherited kidney disease, is characterized by the development of cysts in the kidney that impair function.
- Trial name
- BEAT-PKD (NCT07282821)
- Testing
- Bempedoic Acid 180 MG Oral Tablet
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Kenneth Hallows
Polycystic Liver Disease
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD, either isolated as in autosomal dominant PLD…
- Trial name
- POSITANO (NCT05281328)
- Testing
- CAM2029
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 71 people
- Sponsor
- Camurus AB
Autosomal Dominant Polycystic Kidney
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
- Trial name
- EXPLORE (NCT06496542)
- Testing
- Daily caloric restriction, Standard advice control
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney
Treatment of Vascular Stiffness in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease characterized by cystic kidneys and caused by mutations in the polycystic kidney disease and other rare genes.
- Trial name
- TRAMPOLINE (NCT05228574)
- Testing
- Sodium chloride (NaCl), Amiloride Hcl 5mg Tab
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Erasmus Medical Center
Autosomal Dominant Polycystic Kidney Disease
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This is an exploratory, randomized, double-blind, placebo-controlled, parallel group, multicenter, proof of concept study (Phase 2a), evaluating orally administered GLPG2737 for a double-blind (DB) treatment period of 52 weeks…
- Trial name
- NCT04578548
- Testing
- GLPG2737
- Where
- 20 sites in Belgium, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Lakefront Biotherapeutics NV
Polycystic Kidney, Autosomal Dominant
Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease…
- Trial name
- TEMPO 2:4 (NCT00413777)
- Testing
- Tolvaptan
- Where
- 11 sites in United States
- Volunteers
- 46 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autosomal Dominant Polycystic Kidney Disease
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify…
- Trial name
- NCT02187432
- Where
- 14 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,100 people
- Sponsor
- Andreas L. Serra
Polycystic Liver Disease
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.
- Trial name
- RESOLVE (NCT01354405)
- Testing
- Lanreotide
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Lanreotide In Polycystic Kidney Disease Study
LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular…
- Trial name
- LIPS (NCT02127437)
- Testing
- Lanreotide, saline
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney, Polycystic, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study
We will enroll 20 patients to evaluate the effectiveness of a new operation known as videothoracoscopic splanchnicectomy (VSPL) for management of chronic kidney pain.
- Trial name
- NCT00571909
- Testing
- video thorascopic splanchnicectomy (VSPL)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
ADPKD, Glomerulonephritis
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis.
- Trial name
- NCT00345137
- Testing
- Ng-monomethyl-L-arginine (drug)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
ADPKD
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
This is a retrospective analysis to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of ADPKD and assess the factors that are likely to be associated with the progression…
- Trial name
- ADPKD (NCT02161068)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- The Rogosin Institute
Autosomal Dominant Polycystic Kidney Disease
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys.
- Trial name
- ANCHOR (NCT06902558)
- Testing
- ABBV-CLS-628
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Calico Life Sciences LLC
Autosomal Dominant Polycystic Kidney Disease
Clinical Implications of DNA Analysis on ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease. We plan DNA analysis using the next generation sequencer (NGS) and examine the relationship between mutational types and clinical phenotypes.
- Trial name
- DNAAA (NCT02322385)
- Where
- 2 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Kyorin University
Chronic Kidney Diseases, Diabetes
KidneYou - Innovative Digital Therapy
The aim of the study is to assess the improvement of health in patients affected by CKD when they are exposed to non-pharmacological treatment strategies as nutritional program (NP), physical activity program (PA) and mindfulness…
- Conditions
- Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis
- Trial name
- NCT05286632
- Testing
- KidneYou APP
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Advice Pharma Group srl
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects
- Trial name
- NCT07181265
- Testing
- Amiodarone Hydrochloride Tablets, Febuxostat Tablets
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Canadian Medical Assessment of JINARC™ Outcomes Registry
This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a…
- Trial name
- C-MAJOR (NCT02925221)
- Where
- 6 sites in Canada
- Volunteers
- 530 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.